GSK Acquires Chimagen T-Cell Engager for $750 Million

GSK has entered an agreement to acquire a trispecific T-cell engager from Chimagen Biosciences for up to $750 million. This acquisition aims to expand the company's blood cancer portfolio. The program targets multiple myeloma and is expected to enter Phase I clinical trials in 2027.

"Today’s deal secures a promising T cell engager and advances GSK’s leadership goals in blood cancer. The agreement complements our existing portfolio in multiple myeloma, adding a new potential option to address the different needs of patients facing this complex disease," said Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, in a statement regarding the acquisition.

Financial Structure and Development

The transaction is valued at up to $750 million, consisting of an upfront payment and success-based development and commercial milestones. This acquisition grants GSK full rights to the trispecific T-cell engager. This immunotherapy redirects the immune system to identify and kill cancer cells by binding to both T-cells and tumor cells.

"Working with GSK combines our precision T-cell engager programme with their global development and commercial capabilities to redefine care for multiple myeloma patients," said Zhenhao Zhou, Chief Executive Officer, Chimagen Biosciences.

Market Context

This investment follows a period of strategic focus for GSK as it expands its oncology footprint. The company competes in the multiple myeloma space, where BCMA-targeted treatments are standard. By adding a trispecific engager that interacts with three distinct biological targets, GSK intends to provide a mechanism for disease management that differs from traditional bispecific antibodies.

As of September 17, 2026, GSK PLC-SPON ADR (GSK) shares were trading at $51.06, a 1.53% increase for the day.

Clinical Implications for Multiple Myeloma

Multiple myeloma is an incurable blood cancer characterized by the accumulation of malignant plasma cells in the bone marrow. Research into T-cell engagers often faces challenges regarding patient toxicity and the durability of response. The move into Phase I trials by 2027 will test whether this trispecific platform offers improved efficacy or a more manageable safety profile compared to current clinical options.